Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several general statements about generics and monitoring are not supported or are not verifiable from the provided FDA prescribing information excerpts. Some drug-specific facts (indication, sodium content context, not for acute hyperammonemia, and safety-related GI adverse reactions) are directionally consistent with the label but many claims are outside the supplied label text.
Category Scores
Accurate Statements
Buphenyl is a brand name for sodium phenylbutyrate.
Supported by label identity in the provided context: BUPHENYL (sodium phenylbutyrate).
Sodium phenylbutyrate is a medicine used to treat urea cycle disorders.
Supported: BUPHENYL indicated as adjunctive therapy in chronic management of urea cycle disorders involving CPS, OTC, or AS deficiencies.
Sodium phenylbutyrate helps treat urea cycle disorders by reducing toxic nitrogen levels in the blood.
Partially supported: label states it provides an alternate vehicle for waste nitrogen excretion (via phenylacetylglutamine excretion). Direct phrasing about 'reducing toxic nitrogen levels in the blood' is not explicitly quoted in the excerpt.
A generic version of Buphenyl would contain the same active ingredient (sodium phenylbutyrate) as Buphenyl.
Not verifiable from provided prescribing information excerpts (label excerpt provided does not discuss generics).
Common side effects for this drug class include GI symptoms.
Supported: adverse reactions include gastrointestinal events such as abdominal pain, gastritis, nausea and vomiting, constipation, etc.
In urea cycle disorders, labs/monitoring are used to confirm nitrogen control.
Weak/indirect: label excerpt mentions overdose management includes monitoring ammonia and plasma phenylacetate levels closely; however, it does not provide a general monitoring-to-confirm-nitrogen-control statement in the excerpt.
Unsupported Statements
A generic version of Buphenyl would contain the same active ingredient (sodium phenylbutyrate) as Buphenyl.
The provided FDA label excerpts do not discuss generic substitution or generics' active ingredient equivalence.
A generic should match the brand on the active ingredient (sodium phenylbutyrate).
Not supported in provided prescribing information excerpts.
A generic should match the brand on strength and dosing form.
Not supported in provided prescribing information excerpts.
Differences between generic and brand, if any, are usually in inactive ingredients (for example, tablet/film coating or fillers).
Not supported in provided prescribing information excerpts.
Differences in inactive ingredients typically do not change the medication’s main effect.
Not supported in provided prescribing information excerpts.
Differences in inactive ingredients can matter for people with specific excipient sensitivities.
Not supported in provided prescribing information excerpts.
Many patients can switch between a brand and a generic of the same active ingredient.
Not supported in provided prescribing information excerpts.
Urea cycle disorder therapy is tightly dose-managed.
Not explicitly supported by the provided label excerpts.
Switching between Buphenyl and a generic should involve the prescribing clinician.
Not addressed in provided prescribing information excerpts.
Switching should include dose conversion if product formulation differs.
Not addressed in provided prescribing information excerpts.
Switching should include monitoring response (ammonia and related lab targets).
The excerpt supports ammonia monitoring in overdose management, but does not support a general 'switching' monitoring recommendation.
Switching should include watching for side effects after the change.
Not addressed in provided prescribing information excerpts.
Urea cycle disorder therapy is tightly dose-managed.
The label provides dosing ranges and administration frequency, but does not explicitly support the generalization.
When buying generic Buphenyl, the product label should list the active ingredient as sodium phenylbutyrate.
Not addressed in provided prescribing information excerpts.
When buying generic Buphenyl, the product label should list dosage form and strength (for example, tablet vs granules/other form, mg per unit).
Not addressed in provided prescribing information excerpts.
When buying generic Buphenyl, the product label should list the manufacturer/brand name on the packaging.
Not addressed in provided prescribing information excerpts.
When buying generic Buphenyl, the product label should include directions that match what the clinician prescribed.
Not addressed in provided prescribing information excerpts.
Generic availability varies by country.
Not addressed in provided prescribing information excerpts.
Generic availability varies by what exact product formulation is being considered (tablet vs other formulation).
Not addressed in provided prescribing information excerpts.
Contradictions
Low
AI Statement
Common side effects for this drug class include GI symptoms.
Label Reference
No contradiction found; GI adverse events are listed in the label excerpt.
Important Omissions
The AI claims discuss switching between brand and generic, but the provided label excerpts do not address generic substitution; a label-grounded discussion would need references to label-supported guidance for any switching/transition (if present).
Importance:
Moderate
No AI statement includes the label-supported contraindication that BUPHENYL should not be used to manage acute hyperammonemia (medical emergency).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Most drug- and safety-relevant claims are either unsupported (generic switching guidance and label-purchasing expectations) or only weakly supported by the provided excerpts. The label does include safety cautions and contraindication for acute hyperammonemia, but several high-impact switching/monitoring recommendations are not shown to be supported by the provided prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many claims about generic substitution, switching, and how to assess generic product labeling are not supported by the provided FDA prescribing information excerpts.
Suggested Improvement
Limit claims to elements explicitly supported by the label excerpts (indications, the contraindication for acute hyperammonemia, described cautions, listed adverse reactions, and label-supported dosing/administration where quoted). Remove or qualify statements about generic substitution and country availability unless the label excerpts specifically address them.